Skip to main content
Fig. 7 | Diabetology & Metabolic Syndrome

Fig. 7

From: Enhancing insulin sensitivity in type 2 diabetes mellitus using apelin-loaded small extracellular vesicles from Wharton’s jelly-derived mesenchymal stem cells: a novel therapeutic approach

Fig. 7

Inflammatory cytokine levels in T2DM model mice treated with MSC-sEVs and AP-MSC-sEVs. (a) Reduction in pro-inflammatory cytokine levels with both treatments, although more significantly with AP-MSC-sEVs treatment (P < 0.05), except for IL-6 in the MSC-sEVs group. (b) Serum levels of the anti-inflammatory factor IL-27 decreased slightly, whereas those of IL-10 increased in the T2DM + PBS group; there were significant changes in the levels of the factors under both sEV treatments, with a notable increase in IFN-β levels only in the T2DM + AP-MSC-sEVs group (P < 0.05; *P < 0.05, **P < 0.01, ***P < 0.001). Abbreviations: sEVs, small extracellular vesicles; AP-MSC-sEVs, apelin-MSC-sEVs, engineered sEVs loaded with overexpressed apelin; Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs)

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us